Case | Author (date) | Diagnosis | aPL | Age/sex | Cytopenia | Outcome | Current treatment |
1 | Ballerini et al(1995)18 | PAPS | IgG | 23/F | Thromb | CR | — |
2 | Leuzzi et al(1997)17 | PAPS | IgG, IgM | 35/F | Thromb | CR | — |
3 | Leuzzi et al(1997)17 | PAPS | IgG, IgM | 33/F | Thromb | CR | — |
4 | Hakim et al(1998)19 | PAPS | IgG | 39/F | Thromb | CR | — |
5 | Hakim et al(1998)19 | PAPS | IgG | 23/F | Thromb | CR | — |
6 | Hakim et al(1998)19 | PAPS | IgG | 40/F | Thromb | CR | — |
7 | Hakim et al(1998)19 | SLE | IgG | 37/F | Thromb | CR | Pred, HCQ |
8 | Hakim et al(1998)19 | SLE | IgG | 28/F | Thromb | CR | Pred, MTX |
9 | Hakim et al(1998)19 | SLE | IgG | 40/F | Thromb | CR | Pred, AZA |
10 | Galindo et al(1999)20 | SLE | IgM | 30/F | Thromb | CR | Pred, HCQ |
11 | Galindo et al(1999)20 | SLE | LA | 41/F | Thromb | CR | Pred, HCQ |
12 | Galindo et al(1999)20 | SLE | LA, IgG | 25/F | Thromb | CR | Pred, HCQ |
13 | Galindo et al(1999)20 | SLE | LA, IgG, IgM | 36/F | Thromb | CR | Pred, AZA |
14 | Galindoet al(1999)20 | SLE | LA | 58/F | Thromb | CR | Pred |
15 | Galindo et al(1999)20 | PAPS | LA, IgG, IgM | 35/F | Thromb, HA | CR | Pred |
16 | Galindo et al(1999)20 | SLE | IgG | 47/F | Thromb | CR | HCQ |
17 | Galindo et al(1999)20 | SLE | IgG, IgM | 22/F | Thromb | CR | Pred, CQ |
18 | Galindoet al (1999)20 | SLE | LA, IgG, IgM | 36/F | Thromb, HA | CR | Pred |
19 | Galindoet al(1999)20 | PAPS | LA | 47/M | Thromb | PR | Pred |
20 | Galindo et al(1998)20 | SLE | LA, IgG | 52/F | Thromb | PR | HCQ |
21 | Present study | PAPS | IgM | 60/F | Thromb, HA | CR | — |
22 | Present study | LLD | IgG, IgM | 32/F | Thromb, HA | CR | — |
aPL= antiphospholipid antibodies; PAPS = primary antiphospholipid syndrome; SLE = systemic lupus erythematosus; LLD = lupus-like disease; LA = lupus anticoagulant; F = female; M = male; Thromb = thrombocytopenia; HA = haemolytic anaemia; CR = complete remission; PR = partial remission; Pred = prednisone; HCQ = hydroxychloroquine; MTX = methotrexate; AZA = azathioprine; CQ = chloroquine.